Resume Service
The Following Text Is An Unformatted Professional Resume Sample
From The Writers At Resumes Guaranteed
ORDER YOUR OWN LETTER-PERFECT, JOB-WINNING RESUME AND IT WILL BE COMPLETED AS SOON AS YOU NEED!
Click HERE!
Yyyyyy x. yyyyyy
0000 xxxxxx xxxx , xxxx , xxxxx 00000
abc@xyz.com
(xxx-xxx-xxxx
Country of Citizenship: United States
Veteran s Preference: N/A
Usajobs.com Announcement #: HHS-FDA-09-2008-0143
Core Qualifications/Competencies
Senior Pharmacologist, Senior Toxicologist, Primary Investigator, Pre-Clinical Pharmacology, Clinical Pharmacology, Product Development, Research and Development (R&D), Drug Discovery, Drug Safety, Study/Research Protocol, Report Reviews, Data Interpretation, Product Identification, Health Scientist, Widely Published, Frequent Invited Speaker
Professional Experience
2000 - present
National Institute on Drug Abuse (NIDA), NIH
Bethesda, MD
Division of Pharmacotherapies & Medical Consequences of Drug Abuse (DPMCDA)
Medications Discovery & Toxicology Branch
Supervisor: David J. McCann, Ph.D.; Phone xxx-xxx-xxxx ; Permission to Contact: Yes
Annual Salary: $127K
Hours per week: 40
Health Scientist Administrator
Have proficiently established a cardiovascular drug safety evaluation program, strategically collaborating with invited industry, FDA and academia leaders to define and address key health assessment issues impacting QT/QTc prolongation. Developed in vitro/in vivo studies protocol to evaluate cardiovascular safety studies, with a strong focus on cocaine-medication interactions in monkeys and dogs. Efficiently reviewed and summarized findings/results from toxicology, pharmacokinetic, and toxicokinetic studies conducted under research contracts and in conjunction with projects within the DPMCDA; data from over 150 studies have been subsequently applied toward filing Investigational New Drug Application (INDs) for drug addiction treatment. Applied strong research and analysis skills toward reviewing literature in order to identify medications with novel mode of action that may present potential for preventative and therapeutic treatment of addictive disorders, including food addiction.
1999 - 2000
American Chemistry Council
Arlington, VA
Panel Manager
Comprehensively analyzed, troubleshot and resolved critical issues associated with mammalian toxicology, public health, environment, government, and chemical industry to define optimal research, education and advocacy strategies. Conducted thorough reviews of toxicology reports on fluoro-alkenes and hydrogen sulfide; compiled data and summarized findings for submission to Environmental Protection Agency (EPA).
Page 1 of 5
Yyyyyy x. yyyyyy HHS-FDA-09-2008-0143 - Page 2 of 5
Professional Experience continued
1996 - 1999
Otsuka America Pharmaceutical Inc
Rockville, MD
Supervisor : Norma Browder; Phone: 301-990-0030; Permission to Contact: Yes
Annual Salary: $105K
Hours per week: 40
Associate Director of Drug Safety Evaluation
Studied broad scope of drug candidates for treatment of diverse health/medical issues ranging from congestive heart failure and intermittent claudication to stroke, stenosis and restenosis; research included diuretic pharmaceuticals.
Actively collaborated in preparing Investigational New Drug Applications (INDs), Investigational Drug Brochures (IDBs) and New Drug Applications (NDAs) for multiple cardiovascular drugs. Contributed dynamic leadership skills toward steering contract research laboratory operations targeting evaluation of drug safety and efficacy. Instrumental in attaining approval of Cilostazol (Pletal) for United States as well as global countries.
1981 - 1994
Carter Wallace, Inc.
Cranbury, NJ
Supervisor: Dr. Duane Sofia, Retired; Home Phone: 717-569-4144; Permission to Contact: Yes
Annual Salary: $110K
Hours per week: 40
Director, Department of Pharmacology; 1992-1994
Associate Director, Department of Pharmacology; 1988-1992
Section Leader; 1983-1988
Senior Pharmacologist; 1981-1983
Steadily progressed with company over the course of 13 years, culminating in senior-level position as Director of Pharmacology Department. Led laboratory operations and contract research initiatives, evaluating activity and commercial merits of licensing and acquiring varied compounds. Applied dynamic leadership skills toward effectively directing a top-performing team of research scientists in facilitating complex pharmacological and toxicological studies. Effectively developed/prepared numerous reports, summaries, INDs, and IDBs leading to NDA submissions of anti-allergy, anti-asthma and neuro-protective drugs to US FDA; successfully made a significant contribution to NDA approval of azelastine in Japan and Germany as well as US drugs, Astelin and Felbatol.
Education
University of Guelph, Ontario, Canada
Doctor of Philosophy, Pharmacology
Date: 1978
University of Guelph, Ontario, Canada
Masters of Science, Pharmacology
Date: 1974
Total Credits: 37.5
Key
Coursework: Cardiovascular Physiology, Special Problems in Biomedical Sciences,
Medical Immunology, Advanced Pharmacology II
U.P. Agricultural University, Nainital, India
Masters in Veterinary Science, Pharmacology/Toxicology
Date: 1971
Total Credits: 43
Key Coursework: Correlative Pathology, Pharmacology, Biochemistry, Organic Chemistry, Intermediate Metabolism of Carbohydrates and Fats
Yyyyyy x. yyyyyy HHS-FDA-09-2008-0143 - Page 3 of 5
Education continued
U.P. Agricultural University, Nainital, India
Doctor of Veterinary Medicine
Date: 1969
Total Credits: 150
Key Coursework: Anatomy, Histology, Physiology, Pathology, Necropsy, Medicine, Surgery, Nutrition
GPA: 4.99/5.0
(Academic Background Details Referenced, WORLD EDUCATION SERVICE REPORT, pp 1-7)
Honors/Awards
Graduated 1st in Class amongst 150 Students, DVM Program
Recipient, Gold Medal Award for highest GPA (4.99/5.0)
Donald McQueen Shaver Award, Canada
Senior Research Fellowship, India
Junior Research Fellowship, India
Selected Publications
(10 of 73 in vivo and in vitro publications)
Chand, N., Nolan, K., Pillar, J., Diamantis, W. and Sofia, R.D. (1992). Aeroallergen-induced dyspnea in freely moving guinea pigs: Quantitative measurement by bias flow ventilated whole body plethysmography. Allergy 48:230-235.
Chand, N., Nolan, K., Diamantis, W., Perhach, J.L. Jr. and Sofia, R.D. (1986). Inhibition of leukotriene (SRS-A)-mediated acute lung anaphylaxis by azelastine in guinea pigs. Allergy 41:473-478.
Chand, N., Pillar, J., Diamantis, W., Perhach, J.L. Jr. and Sofia, R.D. (1983). Inhibition of calcium ionophore (A23187)-stimulated histamine release from rat peritoneal mast cells by azelastine: Implications for its mode of action. Eur. J. Pharmacol. 96:227-233.
Chand, N., Adusumalli, V.E., Nolan, K., Diamantis, W., Wichmann, J.K., Pivonka, J., Langevin, C.N., Wong, K.K., Kucharczyk, N. and Sofia, R.D. (1983). Pharmacodynamic and pharmacokinetic studies with azelastine in the guinea pig: Evidence for preferential distribution into the lung. Allergy. 48:19-24.
Chand, N. and Altura, B.M. (1981). Acetylcholine and bradykinin induce relaxation of intrapulmonary arteries by acting on endothelial cells: Role in lung vascular diseases. Science 213:1376-1379.
Chand, N. (1981). Reactivity of isolated trachea, bronchus and lung strip of cats to carbachol, 5-hydroxytryptamine and histamine: Evidence for the existence of methysergide sensitive receptors. Br. J. Pharmacol. 73:853-857
Chand, N., Dhawan, B.N., Srimal, R.D., Rahmani, N.H., Shukla, R.K. and Altura, B.M. (1981). Reactivity of airway smooth muscles to bronchoactive agents in langur monkeys. J. Appl. Physiol. 50:513-516.
Chand, N., Dhawan, B.N., Srimal, R.C., Rahmani, N.H. Shukla, R.K. and Altura, B.M. (1980). Reactivity of trachea, bronchi, and lung strips to histamine and carbachol in rhesus monkeys. J. Appl. Physiol. 49:729-734.
Chand, N. and Altura, B.M. (1980). Reactivity and contractility of rat main pulmonary artery to vasoactive agents. J. Appl. Physiol. 49:1016-1021.
Chand, N. and DeRoth, L. (1979). Dual histamine receptor mechanism in guinea-pig lung. Pharmacology 19:185-190
Yyyyyy x. yyyyyy HHS-FDA-09-2008-0143 - Page 4 of 5
Invited Lectures
(Selected 3 of 23)
Invited Faculty, North American Society for Pacing and Electrophysiology, 24th Annual Scientific Sessions. May 2003.
GBR 12909 (Vanorexine)- pharmacokinetic and toxicokinetic data in relation to QT prolongation. Session on QT Prolonging Drugs - Basic, Clinical and Regulatory Issues.
Medical consequences of obesity and food addiction. Eagleville Hospital, Eagleville, Pennsylvania (April 28, 2006). Prevention of obesity and food addiction. Institute of Management Studies (IMS), Ghaziabad, U.P., India (November 12th, 2007).
IL-5 antibodies and modulation of bronchial eosinophilia. FASEB Summer Research Conference, Sextons River, Vermont (July 10th -15th , 1993).
Book Chapters and Review Articles
(Selected 6 of 15)
Chand, N. and Sofia, R.D. (1994). Histamine: Receptor Subtypes, Signal Transduction and Airway Effects: Airways Smooth Muscle, Vol. 3, ed. D. Raeburn and M.A. Giembycz, Birkhauser, Verlag, AG, Basel, Switzerland.
Chand, N. and Sofia, R.D. (1993). Potential Therapeutic Usefulness of Anti-IL-5 Monoclonal Antibody in Asthma. Drugs of Today 29:477-485
Chand, N. and Sofia, R.D. (1993). Potential Therapeutic Usefulness of Anti-IL-5 Monoclonal Antibody in Asthma. Drugs of Today 29:477-485.
Chand, N., Diamantis, W. and Sofia, R.D. (1990). Airway histamine receptors and their significance in allergic lung diseases. In: Airway smooth muscle: modulation of receptors and response, ed. D.K. Agrawal and R.G. Townley, CRC Press, Inc., p. 259-269.
Perhach, J.L., Chand, N., Diamantis, W., Sofia, R.D. and Rosenberg, A. (1989). Azelastine - a novel oral antiasthma compound with several modes of action. In: Allergy and Asthma - New Trends and Approaches to Therapy, Ed. A.B. Kay, Blackwell Scientific Publications, p. 230-248.
Chand, N., Perhach, J.L., Jr., Diamantis, W. and Sofia, R.D. (1985). Heterogeneity of calcium channels in mast cells and basophils and the possible relevance to pathophysiology of lung diseases: A Review. Agents and Actions 17:407-417.
Continuing Medical Education/CMEs
Coursework
QT and Arrhythmia Issues in Drug Development, FDA/Heart Rhythm Society,
April 7th-8th, 2008
Genetics and Epigenetic of Addiction, NIDA, March 31st - April 4th, 2008
Clinical Pharmacology - Data Analysis: Modeling and Simulation, NIH
October 20-21, 2004
Principles of Clinical Pharmacology, NIH, 2003
The Biologic and Medical Device Approval process, one week training course, August 2000
Regulatory Toxicology, Kansas City, MO, April 1999
Conferences
American Heart Association, Annual Scientific Sessions (1996 C present)
Attended many symposia on the pathphysiology of cardiovascular diseases, atherosclerosis and lipid disorders, metabolic syndrome, obesity etc.
Yyyyyy x. yyyyyy HHS-FDA-09-2008-0143 - Page 5 of 5
Professional Affiliations
Association of Government Toxicologists (2000 C present)
-President; 2005
Councilmember, American Heart Association, Council on Arteriosclerosis, Thrombosis & Vascular Biology; Stroke; Circulation (1997 C 2000)
Pulmonary Research Group
-President, 1990 - 1996
-Board Member, 1996 C 1999
Key Specialties/Professional Interests
Preclinical and clinical pharmacology
Cardiovascular drug safety/toxicology
Cardiovascular diseases and aging
Obesity, metabolic syndrome, diabetes, osteoporosis
Inflammation, allergy, asthma
Drug discovery and development (R&D)
<< Previous Back to Sitemap Next >>
Remember: Hire Us To Write YOUR New Resume
And We GUARANTEE That If You’re Not Working In 60 Days Or Less,
We’ll Revise Your Resume, Refund Your Money,
AND Give You $50 EXTRA!